Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

R932333 · R333

Other · developed by Rigel Pharmaceuticals

Phase 2 Most advanced trial (none active)
RIGL Developer
1 Registered trials

What is R932333?

R932333 (also known as R333) is a drug studied in discoid lupus erythematosus and systemic lupus erythematosus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
R333
Drug type
Other
Therapy area
Immunology
Developer
Rigel Pharmaceuticals (RIGL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01597050 Phase 2 Lupus Erythematosus, Discoid Completed RIGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lupus Erythematosus, DiscoidLupus Erythematosus, Systemic

More from Rigel Pharmaceuticals

Follow RIGL, the company behind R932333

See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RIGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.